• Mashup Score: 0

    Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with solid tumours

    Tweet Tweets with this article
    • #ESMOImmuno21: Amplifying #RNAvaccines the way forward in #CARTcell therapy? Early clinical findings w/ anti-claudin-6 CAR-T-cell product BNT211, w/ or not amplifying vaccine, in pts w/ refractory solid tumours promising but more data needed https://t.co/ZIQK7oPrFM #immunotherapy https://t.co/HoSLTE7EuO